Opinion

Video

Breaking Down the PAH Cost Burden

Marius Hoeper, MD, discusses the direct medical costs and indirect socioeconomic costs associated with the treatment of pulmonary arterial hypertension (PAH), including hospitalizations, outpatient care, and patient productivity and quality of life.

Video content above is prompted by the following questions:

  • What are the direct medical costs and indirect socioeconomic costs associated with managing pulmonary arterial hypertension (PAH), including hospitalizations, outpatient care, and impacts on patient productivity and quality of life?
  • How does the overall burden of PAH, in terms of clinical outcomes and resource utilization, vary across different patient populations and health care settings? Are there any disparities that clinicians and payers should be more aware of?
Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo